Anaplastic Large Cell Lymphoma, ALK-Negative Recruiting Phase 2 Trials for Doxorubicin (DB00997)

Also known as: Anaplastic Large Cell Lymphoma, ALK-negative

IndicationStatusPhase
DBCOND0061449 (Anaplastic Large Cell Lymphoma, ALK-Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03113500Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaTreatment